Drug Trial Radar · NCT06205381
Assessment of the Safety, Tolerability and Pharmacokinetics of AV078 in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Mar 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
89
Actual
Start
Jan 31, 2024
Primary completion
Feb 8, 2025
Study completion Feb 8, 2025
Sponsor
- Lead sponsor
- Aeovian Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 16, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This Phase 1 study in healthy adult volunteers is planned to evaluate the safety, tolerability, and pharmacokinetics (PK) of AV078, a selective inhibitor of mammalian target of rapamycin complex 1 (mTORC1). The study will begin with a standard exploration of safety and tolerability in sequential single ascending dose (SAD) and multiple ascending dose (MAD) cohorts. Subsequent cohorts will collect PK data to evaluate food effects and potential drug-drug interactions relevant to AV078.
Conditions
- Healthy Participants
Interventions
AV078Drug
Oral solution containing active ingredient, AV078
PlaceboDrug
Oral solution with no active ingredients
ItraconazoleDrug
Once daily oral dose of 200 mg itraconazole administered for 9 days
MidazolamDrug
2.5 mg midazolam administered orally on day 1 and day 18
FexofenadineDrug
120 mg fexofenadine administered orally on day 1 and day 18
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of treatment emergent adverse events (TEAEs).Time frame: From screening (Day -42) to final visit post-treatment (Day 14 for Part A and Day 42 for Part B).
- Occurrence of clinically significant changes in physical examination (including neurological assessment).Time frame: From screening (Day -42) to final visit post-treatment (Day 14 for Part A and Day 42 for Part B).
- Change in blood haematology values.Time frame: From screening (Day -42) to final visit post-treatment (Day 14 for Part A and Day 42 for Part B).
- Change in blood biochemisty values.Time frame: From screening (Day -42) to final visit post-treatment (Day 14 for Part A and Day 42 for Part B).
- Change in urinalysis values.Time frame: From screening (Day -42) to final visit post-treatment (Day 14 for Part A and Day 42 for Part B).
- Change in lipid panel values.Time frame: From screening (Day -42) to final visit post-treatment (Day 14 for Part A and Day 42 for Part B).
- Change in blood coagulation values.Time frame: From screening (Day -42) to final visit post-treatment (Day 14 for Part A and Day 42 for Part B).
- Clinically significant ECG findings.Time frame: From screening (Day -42) to final visit post-treatment (Day 14 for Part A and Day 42 for Part B).
- Monitor for the emergence of suicidal ideation and behaviour using the Columbia-Suicide Severity Rating Scale (C-SSRS).Time frame: From screening (Day -42) to final visit post-treatment (Day 14 for Part A and Day 42 for Part B).
- Pharmacokinetics measured by area under the concentration-time curve in fasted and fed state.Time frame: Day 1 to Day 7 post-dose and final follow-up visit (Day 14)
- Pharmacokinetics measured by the maximum plasma concentration (Cmax) in fasted and fed state.Time frame: Day 1 to Day 7 post-dose and final follow-up visit (Day 14)
- Effects of itraconazole on the pharmacokinetics of AV078 measured by area under the concentration-time curve.Time frame: Day 1 to Day 15 post-dose and final follow-up visit (Day 23)
- Effects of itraconazole on the pharmacokinetics of AV078 measured by the maximum plasma concentration (Cmax).Time frame: Day 1 to Day 15 post-dose and final follow-up visit (Day 23)
- Effects of AV078 on the pharmacokinetics of midazolam and fexofenadine measured by area under the concentration-time curve.Time frame: Day 1, 2, 18 and 19 post-dose (midazolam) or Day 1-3, 18 and 19 post-dose (fexofenadine)
- Effects of AV078 on the pharmacokinetics of midazolam and fexofenadine measured by the maximum plasma concentration (Cmax).Time frame: Day 1, 2, 18 and 19 post-dose (midazolam) or Day 1-3, 18 and 19 post-dose (fexofenadine)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Q-Pharm
Herston, Queensland, Australia
Nucleus Network Pty Ltd
Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.